After Dr. Sylke Hassel’s exclusive interview at CPHI Worldwide, Arul Ramadurai, CCO at Axplora, also spoke on camera to share his business vision. This interview takes us on a journey through Axplora’s legacy forged through the integration of Farmabios, Novasep, and Pharmazell, and how this heritage forms the bedrock of Axplora’s commercial strategy.
In essence, the three legacy brands have come together to offer both API products to generic companies and CDMO services to innovative big pharma and biotech companies and thus support the entire lifecycle of pharmaceutical products.
Arul underlines the unbreakable link between patients’ security and our sites’ audits and certifications to meet the customers’ expectations. And for him, security supply, high quality, and products on time are the basics that set Axplora apart as a Reliable Partner.
Last point but not least, Arul provides a glimpse into Axplora’s Environmental, Social, and Governance (ESG) strategy, not only expected by customers but also core to “our being”. Indeed, as a player in the pharmaceutical industry, Axplora is actively looking for more sustainable and cost-efficient solutions such as electrochemistry where the company has gained a unique experience and expertise to match the increased complexity of new APIs being developed.
Latest news
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
News
March 17, 2026
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site 18 February, 2026 – Axplora, a global CDMO Partner for complex small molecules and antibody-drug conjugates (ADCs), today announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France Site strengthening its ability to deliver […]
Press Release
October 08, 2025
Axplora initiates global investments exceeding €100m in 2025
Raubling, 7 October, 2025 – Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.